Business Context and Reporting Period
Company: EyePoint Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 15, 2019
Event: Appointment of a new director and changes to Board composition.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and director compensation.
Material Changes
- Board Expansion: The Board of Directors increased its size from nine to ten members.
- New Appointment: Wendy DiCicco was appointed to fill the newly created vacancy, effective immediately.
- Committee Role: Ms. DiCicco was appointed Chairperson of the Audit Committee.
Compensation and Governance Details
Ms. DiCicco's compensation package includes:
- Cash Retainer: $40,000 annually for general board participation.
- Committee Retainer: $20,000 annually for serving as Audit Committee Chair.
- Stock Option Grant: Option to acquire 80,000 shares of common stock.
- Option Terms:
- Exercise Price: $1.51 per share (closing price on July 15, 2019).
- Vesting: Three equal annual installments commencing on the first anniversary of the grant date.
- Term: Exercisable for 10 years from the date of grant.
- Indemnification: An indemnification agreement was executed, consistent with those for other directors.
Investor Verification Checklist
- Verify the impact of the new Audit Committee Chair on the company's financial oversight processes.
- Review the 2016 Long Term Incentive Plan (referenced in the filing) to confirm the specific terms governing the stock option grant.
- Monitor future filings for the vesting schedule execution of the 80,000 share option grant.
- Confirm that no undisclosed relationships or transactions exist involving the new director as stated in the filing.